CNMD Earnings Date: Jan 27, 2027 (Estimated) — CONMED Corporation
NYSE · Healthcare · Medical Devices
Updated
When is CNMD's next earnings date?
CONMED Corporation (CNMD) is expected to report Q4 2026 earnings on Wednesday, January 27, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.27 on revenue of $369.1M.
How did CNMD do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), CONMED Corporation posted EPS of $1.04 versus the $1.00 estimate, a beat of 4.0%. Revenue was $335.6M against a $336.3M estimate. The stock's 1-day post-earnings move was -0.1%.
How much does CNMD stock move after earnings?
CNMD beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.7% (up or down) in the day after earnings.
About CONMED Corporation
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
🤖 AI Earnings Analysis
Conmed’s Q3 was mixed: EPS of $1.04 beat estimates by $0.04, but revenue slipped 0.6% year over year to $336 million and missed the forecast. The medical-device maker’s full-year EPS outlook of $4.48–$4.60 offers limited reassurance amid soft sales.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | 1.00 | 1.04 | +4.00% | $335.6M | ✅ Beat | -0.09% | — | — |
| 2026-07-29 | Q2 2026 | 1.11 | 1.38 | +24.32% | $343.5M | ✅ Beat | +8.72% | +14.09% | +16.45% |
| 2026-04-29 | Q1 2026 | 0.82 | 0.89 | +8.54% | $317.0M | ✅ Beat | +1.95% | +3.78% | -0.72% |
| 2026-01-28 | Q4 2025 | 1.32 | 1.43 | +8.33% | $373.2M | ✅ Beat | -3.57% | +3.21% | +18.89% |
| 2025-11-05 | Q3 2025 | 1.05 | 1.08 | +2.86% | $337.9M | ✅ Beat | -0.52% | -1.98% | -9.83% |
| 2025-07-30 | Q2 2025 | 1.13 | 1.15 | +1.77% | $342.3M | ✅ Beat | +2.02% | +1.84% | +7.17% |
| 2025-04-30 | Q1 2025 | 0.81 | 0.95 | +17.28% | $321.3M | ✅ Beat | +16.45% | +14.05% | +15.55% |
| 2024-10-30 | Q3 2024 | 0.99 | 1.05 | +6.06% | $316.7M | ✅ Beat | +4.57% | +15.91% | +13.45% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $335.6M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| General Surgery | 55.6% | $186.7M | -6.5% | $183.0M | $201.6M | $199.7M | $215.8M |
| Orthopedic Surgery | 44.4% | $148.8M | +7.7% | $138.3M | $140.7M | $138.2M | $157.4M |
By region
Q3 FY26 · $335.6M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 51.5% | $172.7M | -11.0% | $183.8M | $190.6M | $194.0M | $206.2M |
| EMEA | 20.2% | $67.6M | +15.2% | $63.7M | $67.8M | $58.7M | $74.5M |
| Asia Pacific | 18.0% | $60.4M | +12.2% | $43.7M | $52.1M | $53.8M | $59.1M |
| Americas (excluding the United States) | 10.4% | $34.9M | +10.9% | $30.1M | $31.9M | $31.4M | $33.3M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.